Happy Friday, and welcome back to #PiperComm’s roundup of News in the Industry! ⚡️
🦿 Knoxville-based Orion Therapeutics was selected as one of five companies to present in the Healthcare, Assistive Tech, and BioTech category at the South by Southwest pitch showcase next month in Austin.
⚡️ The Tennessee Valley Authority is shifting its energy priorities after its first board meeting since the quorum was restored. Check out these five things to watch for as TVA readjusts its energy goals.
🤝 Oak Ridge National Laboratory and Kairos Power have formed a $27 million strategic partnership to accelerate the technology needed to deploy a new generation of advanced nuclear reactors and support U.S. nuclear energy goals.
Read more about each story at the link in our bio! 🔗
In this video, Mike Urbanski explains how the Biopharma Center of Excellence in Northborough, Massachusetts, is dedicated to serving the life science and biopharma industries.
#ProtectingtheEssential #TrelleborgLife #TrelleborgMedicalSolutions
🚨🙌NEW: £12.9 million investment for Lisburn company branded a “game changer”
💰A £12.9 million investment by Cirdan Imaging will enhance the company’s innovation and skills, improve the efficiency of its laboratory information system (LIS), and create 72 new jobs in Lisburn.
The investment has been announced by First Minister Michelle O'Neill, deputy First Minister Emma Little-Pengelly, and Economy Minister Caoimhe Archibald.
Chief Reporter James Gould spoke to the Ministers, Alison Currie, Chief Development Officer at Invest NI and Hugh Cormican, CEO of Cirdan.
Cirdan is a leading pathology company aiming to enhance diagnosis for patients with cancer and other diseases.
The company’s LIS helps make patient diagnosis faster and more accurate by improving clinical workflows and reducing costs worldwide.
The project will create 72 roles, including Clinical Laboratory Analysts, Project Managers, Integration Managers, Instrumentation Engineers, AI Engineers, and Software Engineers.
The company hopes to fill the roles by 2028.
The west deserves the best. And that’s why a re-elected Malinauskas Labor Givernment will deliver a dedicated 24/7 pharmacy for the western suburbs. For families, for working people, for all of us - when you need it, where you need it.
🔍 New Ipsos polling is in 🔍
Bruce, Grey and Huron communities continue to show strong support for Bruce Power and growing momentum for Bruce C.
Here’s what residents are saying:
☑️ 86% support new nuclear
☑️ 88% say expansion is needed
☑️ 91% see community benefits
☑️ 96% expect local jobs
A strong foundation for the future.
🔗 Read more in Newsroom link in our bio.
Two things that have been important along the way, and are instrumental to the success of everything we do:
1. Robust data
2. Strong partnerships
@Ulsteruni / @QUbelfast / @invest_ni
Last year, I announced alongside @repschweyer $11.7M in PENNVEST funding to tackle PFAS contamination in Emmaus’s water supply.
Today, that commitment is becoming reality:
✅ Major upgrades at 101 Klines Lane and the Main Pumping Station
🚰 Installation of 4 large granular-activated carbon filter tanks
Since taking office, addressing PFAS has been a top priority. Working with borough officials and Rep. Schweyer, we fought to secure PENNVEST resources for this essential project because every family deserves safe, clean drinking water.
Percheron Therapeutics (ASX:PER) is an international biotechnology company developing novel therapies for oncology and rare diseases. During the December 2025 quarter, the Company reported final Phase I data for HMBD-002, confirming strong safety and encouraging efficacy signals, and outlined a modular Phase II clinical trial with manufacturing scheduled for the second quarter of this year and ahead of Wholesale Investor’s Emergence 2026 Conference, CEO and Managing Director Dr James Garner speaks with The Stock Network’s Lel Smits about clinical progress and the path into Phase II.
⚗️ Phase I results and clinical validation
🧪 Phase II strategy and near-term catalysts
👉 Wholesale Investor's Emergence 2026
🗓 18-20 February, 2026
📍 Four Seasons Hotel, Sydney
2025 was another exciting year at @civica_rx
To date, we've delivered more than 250 million vials of essential generic medicines, enough to serve more than 95 million patients...and our work isn't done. Have a look at the attached video and see how we make a difference in the lives of patients.
Michael Hogue, CEO of the American Pharmacists Association, reflects on changes approved by Council to FIP’s voting structure. The new approach ensures more equitable representation for member organisations of all sizes, so that pharmacists from every country have a stronger and fairer voice in shaping FIP’s policies and decisions.